NCT01427751 - Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion | Biotech Hunter

Enrollment

307

Participants

Timeline

Start Date

October 11, 2011

Primary Completion Date

November 4, 2014

Study Completion Date

November 4, 2014

Conditions

Retinal Vein OcclusionMacular Edema

Interventions

DRUG

dexamethasone intravitreal implant

Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.

BIOLOGICAL

ranibizumab

Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.

Trial Locations (6)

Unknown

Paris

Munich

Tel Aviv

Milan

Madrid

London